Overview

* Exagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectations

* Company reports net loss for Q3 2025 despite revenue growth

* Exagen expands AVISE CTD test volume and ASP in Q3 2025

Outlook

* Exagen ( XGN ) reiterates 2025 revenue guidance of $65 mln to $70 mln

* Company expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of range

Result Drivers

* AVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024

* ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $17.24 $16.90

Revenue mln mln (8

Analysts

)

Q3 EPS -$0.31

Q3 Net -$7.08

Income mln

Q3 $13.17

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Exagen Inc ( XGN ) is $12.00, about 1.4% above its November 3 closing price of $11.83

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)